Caroline Jamison*, Debra Nelson†, Mete Eren†, Dron Gauchan†, Ryan Ramaekers†, Max Norvell†, Mehmet Sitki Copur†
Oncology Research, Vol.23, No.1-2, pp. 1-5, 2015, DOI:10.3727/096504015X14452563485986
Abstract Efficacy and safety of dasatinib in chronic phase (CP) chronic myelogenous leukemia (CML) patients has
been well established. Initially approved dose and schedule of 70 mg twice daily has been changed to 100 mg
once daily after demonstration of the same efficacy with less toxicity. Some patients require significant dose
reductions to enable continued treatment with dasatinib. Even at a dose of 80 mg once daily, several patients
may require further dose reductions due to substantial toxicity while maintaining good control of their disease.
We report two CP-CML patients achieving and maintaining major molecular responses More >
Login
Register
